A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma



Status:Archived
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:March 2009
End Date:September 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma


This study will evaluate the efficacy and safety of entinostat, SNDX-275, in patients with
relapsed or refractory Hodgkin's lymphoma.



We found this trial at
6
sites
Roswell Park Cancer Center Institute
Elm St,
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Center Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland 21231
410-955-6190
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
M. D. Anderson Cancer Center
1400 South Orange Avenue
Orlando, Florida 32806
407-648-3800
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Tower Cancer Research Foundation
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
University of Colorado, Boulder
Boulder, Colorado 80309
(303) 492-1411
University of Colorado, Boulder As the flagship university of the state of Colorado, CU-Boulder is...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
University of Nebrasaka Medical Center
Omaha, Nebraska 68198
?
mi
from
Omaha, NE
Click here to add this to my saved trials